Insmed Incorporated  

(Public, NASDAQ:INSM)   Watch this stock  
Find more results for INSM
29.70
-0.69 (-2.27%)
After Hours: 29.70 0.00 (0.00%)
Nov 21, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 29.23 - 30.79
52 week 11.49 - 32.94
Open 30.42
Vol / Avg. 1.74M/586,839.00
Mkt cap 2.27B
P/E     -
Div/yield     -
EPS -3.12
Shares 76.59M
Beta 1.14
Inst. own 98%
Nov 29, 2017
Insmed Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference - 1:35PM EST - Add to calendar
Nov 14, 2017
Insmed Inc at Stifel Healthcare Conference
Nov 2, 2017
Q3 2017 Insmed Inc Earnings Release
Nov 2, 2017
Q3 2017 Insmed Inc Earnings Call - Webcast
Sep 27, 2017
Insmed Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 25, 2017
Insmed Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 5, 2017
Insmed Inc Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.94% -59.30%
Return on average equity -71.80% -75.62%
Employees 161 -
CDP Score - -

Address

10 Finderne Ave Bldg 10
BRIDGEWATER, NJ 08807-3365
United States - Map
+1-908-9779900 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Officers and directors

William H. Lewis President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Paolo Tombesi Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
S. Nicole Schaeffer Senior Vice President- Human Resource and Corporate Services
Age: 48
Bio & Compensation  - Reuters
Walter Perkins Ph.D. Chief Technology Officer
Bio & Compensation  - Reuters
Eugene Jeffrey Sullivan M.D. Chief Product Strategy Officer and Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Mark Quigley Vice President- Quality Assurance
Age: 63
Bio & Compensation  - Reuters
Christine A. Pellizzari General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Roger Adsett Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Paul Streck Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Donald J. Hayden Jr. Non-Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters